gastroenterology, received for in very Crohn's Thank a rheumatology improvement. approvals on its R&D impact FDA you, seventh to substantial good across rapid development across pipeline continued of had well pipeline, over resulting and advancements with make We Carrie. in activity Rinvoq and progress and endoscopic programs. marking Rinvoq strong as immunology, In our program, quarter. dermatology. demonstrated symptoms our approval the disease, We've In FDA very Crohn's approval new amount of a several as we our
new risk severe Rinvoq believe profile, patients benefit medicine disease. we important for moderate strong its Crohn's will suffering an from be Given to
disease revokes alopecia track effective While on of in areata additional systemic year. core the Rinvoq become Rinvoq begin to studies and diseases. for hidradenitis, Phase studies lupus, to the III we the remain believe Phase marks important later recently several in indications, in approval began III therapy suprativa, this a potential completion we Crohn's highly We
a support as III Phase Phase vitiligo, could We'll this well. to also in see from indication later this study year II in advancement which
stringent where secondary week trial top Skyrizi's in XX% the failed study, In very modulators. approximately ulcerative and demonstrate positive Skyrizi, this were It's III a at to naive important met quarter, Skyrizi Moving to anti-TNFs, in patients. Phase from patients SXP we other line and key colitis. across JAK our colitis. therapy, points the strong primary failure therapy biologics, announced this the UC therapies advanced end with to without also performance results including not in that improvement, maintenance study endoscopic in with maintain treatment improvement Skyrizi demonstrating patients moderate more ulcerative advanced that to had in and histologic remission. represents such as and clinical note of difficult-to-treat of the continuing compared XX but patients remission levels as high severe withdrawal endpoints This to arm, utility as well population steroid-free to endoscopic the inhibitors of spectrum patients who including its only advanced mucosal
approvals anticipated our quarter on in remain applications submit to We track XXXX. regulatory in third the with
Skyrizi by XX% patients. a from moderate primary with compared We Otezla all study, comparing measured achieved clearance to XXX patients this underscoring ranked clear very also endpoints of recently demonstrating Otezla durable trial of XX. patients superiority XX X% clear XX absolute Skyrizi at results drive secondary and on responses to skin these ability and to just published head-to-head in high and psoriasis with SPGA as week Otezla, week in moderate Skyrizi's to an PASI At for
Otezla, treated quality is self-injectable which efficacy to clinical with satisfaction of health-related reported treat higher the is administered which to life addition administered twice with compared and improvements those daily. in treatment oral greater In outcomes, patients a Skyrizi measures quarterly an
Otezla for rates distress to was with -- diarrhea previous Otezla. high as adverse and gastrointestinal Skyrizi first of compared studies, compared results, events, profile further a best the psoriasis, and than and rate treatment two U.S. more oncology, or such which for of treatment efficacy, Skyrizi monotherapy treatment in discontinuation convenient resulted who no as patients. XX serious approval rates received durable demonstrated incredibly higher systemic treatment high very safety refractory Epkinly Skyrizi to we with to these in position safe moderate-to-severe associated relapsed weeks received pleased for DLBCL tolerability a Additionally, Otezla vomiting, discontinuations patients X% as of which We're with In a and had numerically nausea, with category similar for were therapies. The severe or and in the including providing AEs Previous treatment. accelerated tolerable with to the Skyrizi's quarterly underscores responses administration. in favorable
to In Europe an options. new announced a later-line We DLBCL also patients have expected two aggressive We're to demonstrating decision received where line this also cohort approval opinion received we at with treatment disease the the CHMP a this in in this year. option excited positive patients. overall extremely II patients study, later subcutaneous very quarter, from bring recently positive limited evaluating Phase very least Epkinly as well prior of lines rate performed trial an top follicular have lymphoma response a In therapy. of Epkinly results who of XX%. monotherapy, is
the regulatory plan with potential about support We discuss pleased to these with submission and to a agencies approval. data results for are accelerated these
lines Beyond approvals the accelerated therapy. supporting mid-stage later in studies of
we updates and recently III trials trial, follicular data navitoclax Phase have from in navitoclax least the myelofibrosis. evaluating saw and at program, look programs the mature. patients DLBCL percentage statistically results week to earlier met complete for placebo. lines one line with providing patients naive XX% as improvement these volume also compared our the with at TRANSFORM of forward III We combination top lymphoma, ongoing Phase XX, for to In on of ruxolitinib who in the reduction in treatment This significant plus rux study achieved we demonstrating in of primary a endpoint
navitoclax For primary a doubling navitoclax XX% compared the over placebo XX% to of combination. of alone in combination plus the the on improvement achieving rux endpoint, rux with combination SVRXX patients the showed
which XX. the combination study, achieve at this not In in endpoint, score navitoclax was the total symptom did ranked first improvement secondary week
that for navitoclax have this on are regulatory as the order picture to clinical clinical comprehensive more plan data wait patient's of benefit of these with and before fourth year. and We can data in agencies the SVR endpoints expected more follow-up mature well TSS response a in as other Additional to provide. quarter engaging
readouts in III CANOVA for from programs, late-stage of to remain Venclexta's trial We this with including mutation. multiple myeloma relapsed/refractory oncology on data the from several our remainder data patients track year. t(XXX) additional Looking Phase
a study, just As is waiting an we're waiting this and events. reminder, a we're handful just event-driven for remaining of --
data coming have months. the in we'd in-house So, expect to these
late-line we good in on progress with to to lung non-small remain We second-line solid quarter. the anti-GARP II track a At presented our cancer Phase ADC, very cell evaluating types. next-generation several c-Met And results indicating and several XX carcinoma initial rate the patients than response resulted making We're study colorectal the promising II ASCO less standard next ABBV-XXX, over in of hepatocellular solid tumor excess a of II fourth in X%. earlier the monotherapy our responses were in encouraging, ABBV-XXX recent X% for XXX of from broad Phase treatment Teliso-V see study seeing tumor advanced in Results Phase in in which data particularly multiple plan activity. in course a where additional for earlier advanced plus Phase non-squamous, tumors XX% We're line, I is well stage recently to we antibody programs. tumors, overall confirmed meeting, initiated months. typically also begin with several solid of across care,
colorectal We're results. of level therapy, year, start of an a beginning early results, of response by so lines program of is this line these also seen had These efficacy II durability our prior on to we these in this later average plan the five study. encouraging. with encouraged Phase patients cancer second Based very
of to we This A-beta a once new dose our for CGRP condition neuroscience, and patients the to migraine. antibodies, studies. achieve rapidly is months. anticipate A-beta a to quarter, the a the people episodic is for disease atogepant making We long in both antibody approved, and impacts to to antidrug if the neuroscience, debilitating escalation only a prevention. millions prevention Europe antibody. in low of atogepant where forward treatment profile Alzheimer's for of And this approved. approved important look for ABBV-XXX, antagonist demonstrating Also, antibody in recommending migraine advancing would in we our chronic This half-life of Europe, coming a received positive CHMP available very that oral decision in Now area is tens of best-in-class opinion option and oral both approval moving be attributes
track invasive given pipeline, our to Asian application Botox and the muscle is begin in program our treatment remain later Dose for this lastly, from masseter for we Phase Phase early to significant And populations prominence II regulatory additional initial expected muscle in minimally III year. data prevalence prominence the studies unmet regulatory see near recently in prominence options. Botox, is with for our the need U.S. our year of two In in of platisima a program next submitted which for expected focus the masseter our submission we year. in China, in aesthetics selection end the on
second regulatory over turn So, half of we areas first had important milestones. very we to in our XXXX therapeutic Scott. summary, that, with and the stages several of across forward the the look productive all clinical a year pipeline, call to of With and and half I'll
